Citadel Advisors’s NanoViricides NNVC Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | – | Sell |
-79,915
| Closed | -$83.6K | – | 13805 |
|
|
2025
Q4 | $90.3K | Buy |
79,915
+63,154
| +377% | +$88.7K | ﹤0.01% | 11719 |
|
|
2025
Q3 | $24K | Buy |
+16,761
| New | +$25.1K | ﹤0.01% | 12454 |
|
|
2024
Q2 | – | Sell |
-21,489
| Closed | -$24.9K | – | 15027 |
|
|
2024
Q1 | $24.9K | Buy |
21,489
+4,668
| +28% | +$5.35K | ﹤0.01% | 12851 |
|
|
2023
Q4 | $17.2K | Buy |
+16,821
| New | +$19.4K | ﹤0.01% | 12757 |
|
|
2023
Q2 | – | Sell |
-15,205
| Closed | -$17.8K | – | 14951 |
|
|
2023
Q1 | $17.8K | Sell |
15,205
-73,007
| -83% | -$98.5K | ﹤0.01% | 13147 |
|
|
2022
Q4 | $97.9K | Buy |
88,212
+52,323
| +146% | +$81.6K | ﹤0.01% | 11252 |
|
|
2022
Q3 | $62K | Buy |
+35,889
| New | +$78.2K | ﹤0.01% | 11474 |
|
|
2022
Q1 | – | Sell |
-13,615
| Closed | -$31.8K | – | 14252 |
|
|
2021
Q4 | $51K | Buy |
+13,615
| New | +$62K | ﹤0.01% | 13242 |
|
|
2021
Q2 | – | Sell |
-30,342
| Closed | -$122K | – | 14155 |
|
|
2021
Q1 | $143K | Buy |
+30,342
| New | +$137K | ﹤0.01% | 12103 |
|
|
2020
Q4 | – | Sell |
-10,404
| Closed | -$37.9K | – | 11313 |
|
|
2020
Q3 | $40K | Buy |
+10,404
| New | +$57K | ﹤0.01% | 9679 |
|
|
2020
Q2 | – | Sell |
-21,236
| Closed | -$122K | – | 10273 |
|
|
2020
Q1 | $122K | Buy |
+21,236
| New | +$150K | ﹤0.01% | 8477 |
|
|
2019
Q1 | – | Sell |
-3,472
| Closed | -$14K | – | 9673 |
|
|
2018
Q4 | $14K | Buy |
3,472
+1,214
| +54% | +$7.78K | ﹤0.01% | 8857 |
|
|
2018
Q3 | $16K | Buy |
2,258
+709
| +46% | +$5.46K | ﹤0.01% | 9051 |
|
|
2018
Q2 | $14K | Buy |
+1,549
| New | +$19K | ﹤0.01% | 8699 |
|
|
2018
Q1 | – | Sell |
-2,988
| Closed | -$53K | – | 8610 |
|
|
2017
Q4 | $53K | Buy |
+2,988
| New | +$61.1K | ﹤0.01% | 7612 |
|
|
2017
Q3 | – | Sell |
-591
| Closed | -$16K | – | 7858 |
|
|
2017
Q2 | $16K | Buy |
+591
| New | +$14.6K | ﹤0.01% | 7332 |
|
|
2016
Q2 | – | Sell |
-955
| Closed | -$42K | – | 7202 |
|
|
2016
Q1 | $42K | Buy |
955
+58
| +6% | +$2.25K | ﹤0.01% | 6289 |
|
|
2015
Q4 | $21K | Buy |
897
+655
| +271% | +$15.7K | ﹤0.01% | 7892 |
|
|
2015
Q3 | $6K | Buy |
+242
| New | +$6.4K | ﹤0.01% | 8598 |
|
|
2014
Q4 | – | Sell |
-405
| Closed | -$24K | – | 8649 |
|
|
2014
Q3 | $24K | Sell |
405
-1,081
| -73% | -$84.9K | ﹤0.01% | 7325 |
|
|
2014
Q2 | $125K | Sell |
1,486
-553
| -27% | -$39.3K | ﹤0.01% | 6038 |
|
|
2014
Q1 | $131K | Buy |
+2,039
| New | +$174K | ﹤0.01% | 5924 |
|
Other funds holding NNVC
VCM
MFS
VFT
Citadel Advisors's NNVC Position: Q1 2026 in Review
Citadel Advisors sold out of NanoViricides (NNVC) in Q1 2026, closing a stake of 79,915 shares — an estimated $83.6K sold.
Citadel Advisors first reported a position in NNVC in Q1 2014 and held it in 22 quarters. The position peaked at $143K in Q1 2021. 48 funds tracked by Wall St. Rank hold NNVC as of Q1 2026.
- Citadel Advisors reported no remaining NanoViricides position as of Q1 2026 after selling out during the quarter.
- Citadel Advisors sold 79,915 NanoViricides shares in Q1 2026, an estimated $83.6K.
- Citadel Advisors first reported a position in NanoViricides in Q1 2014 and held it in 22 quarters.
- Citadel Advisors's NanoViricides position peaked at $143K in Q1 2021.
- 48 funds tracked by Wall St. Rank held NanoViricides as of Q1 2026.
Based on Citadel Advisors's 13F filing for Q1 2026, filed 15 May 2026.